Abstract:We aimed to evaluate the expression of microRNA-182 (miR-182) in triple-negative breast cancer (TNBC) tissues and the TNBC cell line MDA-MB-231 and to investigate the effects of mirR-182 on the cellular behavior of MDA-MB-231 and the expression of the target gene profilin 1 (PFN1), thus providing new methods and new strategies for the treatment of TNBC. Quantitative real-time PCR (qRT-PCR) was utilized to evaluate the expression of miR-182 in TNBC tissues, relatively normal tissues adjacent to TNBC and the TNBC cell line MDA-MB-231. Forty-eight hours after the MDA-MB-231 cells were transfected with the miR-182 inhibitor, qRT-PCR was utilized to detect the changes in miR-182 expression levels, and an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was utilized to determine the effects of miR-182 on cell viability. Flow cytometry was adopted to determine whether miR-182 affects the proliferation rates and apoptosis levels of the MDA-MB-231 cells. The transwell migration assay method was used to investigate the effects of miR-182 on the migration of the MDA-MB-231 cells. A luciferase reporter gene system was applied to validate that PFN1 was the target gene of miR-182. Western blot was used to measure the effects of miR-182 on the PFN1 protein expression levels in the cells. qRT-PCR results showed that compared with the relatively normal tissues adjacent to TNBC, miR-182 expression was significantly increased in the TNBC tissues and the MDA-MB-231 cells (p<0.01). Compared with the control group, MDA-MB-231 cells transfected with the miR-182 inhibitor and incubated for 48 h showed significantly decreased miR-182 expression (p<0.01). The results of an MTT assay showed that inhibition of miR-182 in MDA-MB-231 cells led to significantly reduced cell viability (p<0.05). Flow cytometry analysis indicated that inhibition of miR-182 expression resulted in significantly decreased cell proliferation (p<0.05) and significantly increased levels of apoptosis (p<0.05). The results of a transwell migration assay showed that after inhibited of miR-182 expression, the number of cells passing through the transwell membranes was significantly decreased (p<0.05). The results from a luciferase reporter gene system showed that compared with the control group, the relative luciferase activity of the group transfected with the miR-182 inhibitor was significantly increased (p<0.05). Western blot analysis showed that compared with the control group, PFN1 protein expression levels were significantly increased in the MDA-MB-231 cells transfected with the miR-182 inhibitor and incubated for 48 h (p<0.05). In conclusion, miR-182 is upregulated in TNBC tissues and cells. It promotes the proliferation and invasion of MDA-MB-231 cells and could negatively regulate PFN1 protein expression. Treatment strategies utilizing inhibition of miR-182 expression or overexpression of the PFN1 gene might benefit patients with TNBC.

Mir-195/Mir-497 Regulate CD274 Expression of Immune Regulatory Ligands in Triple-Negative Breast Cancer

Integrative study reveals the prognostic and immunotherapeutic value of CD274 and PDCD1LG2 in pan-cancer

Mir-143-3p Targeting LIM Domain Kinase 1 Suppresses the Progression of Triple-Negative Breast Cancer Cells.

Mir-433 Inhibits Breast Cancer Cell Growth Via the MAPK Signaling Pathway by Targeting Rap1a

Mir-149-3p Reverses Cd8(+) T-Cell Exhaustion By Reducing Inhibitory Receptors And Promoting Cytokine Secretion In Breast Cancer Cells

MiR-133a/CD47 axis is a novel prognostic biomarker to promote triple negative breast cancer progression

Identification of Six N7-Methylguanosine-Related Mirna Signatures to Predict the Overall Survival and Immune Landscape of Triple-Negative Breast Cancer Through in Silico Analysis

An Integrated Bioinformatics Analysis to Investigate the Targets of Mir-133A-1 in Breast Cancer

Regulation of Cancerous Progression and Epithelial-Mesenchymal Transition by Mir-34C-3p Via Modulation of MAP3K2 Signaling in Triple-Negative Breast Cancer Cells.

Mir-892b Silencing Activates Nf-Kappa B And Promotes Aggressiveness In Breast Cancer

An Integrative Bioinformatics Analysis Identified Mir-375 As a Candidate Key Regulator of Malignant Breast Cancer

p53 downregulates PD-L1 expression via miR-34a to inhibit the growth of triple-negative breast cancer cells: a potential clinical immunotherapeutic target

Expression Of Mir-146a In Triple Negative Breast Cancer And Its Clinical Significance

Analysis of MiR-195 and MiR-497 Expression, Regulation and Role in Breast Cancer.

PDL1 and LDHA Act As Cernas in Triple Negative Breast Cancer by Regulating Mir-34A

MiR-93-5p regulates tumorigenesis and tumor immunity by targeting PD-L1/CCND1 in breast cancer

Tumor-promoting Properties of Mir-8084 in Breast Cancer Through Enhancing Proliferation, Suppressing Apoptosis and Inducing Epithelial–mesenchymal Transition

MIR4435-2HG: A novel biomarker for triple-negative breast cancer diagnosis and prognosis, activating cancer-associated fibroblasts and driving tumor invasion through EMT associated with JNK/c-Jun and p38 MAPK signaling pathway activation

Expression and Regulatory Function of Mirna-182 in Triple-Negative Breast Cancer Cells Through Its Targeting of Profilin 1

Identification of Chemoresistance-Associated Mirnas in Breast Cancer

Bioinformatics Identification of Dysregulated Micrornas in Triple Negative Breast Cancer Based on Microrna Expression Profiling.